(BUSINESS WIRE)–Jan. 27, 2015– Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the fourth quarter and fiscal year 2014. Fourth quarter 2014 results: Revenue of $512 million, a 32% increase compared to $387 million in the fourth quarter of 2013 GAAP net income for the quarter of $153 million, or $1.03 per diluted share, compared to $81 million, or $0.56 per diluted share, for the fourth quarter of 2013 Non-GAAP net income for the quarter of $129 million, or $0.87 per diluted share, compared to $65 million, or $0.45 per… Read more »
Shares of Illumina opened today at $198.9 and are currently trading up at $203.11. ILMN has a 1-year high of $206 and a 1-year low of $127.69. The stock’s 50-day moving average is $188.07 and it’s 200-day moving average is $178.13.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report issued on January 6, J.P. Morgan analyst Tycho Peterson assigned a Buy rating on ILMN, with a price target of $270, which implies an upside of 35.7% from current levels. Separately, on November 28, Wedbush’s Zarak Khurshid maintained a Buy rating on the stock and has a price target of $200.
Illumina, Inc., is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function.